<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="194">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01578668</url>
  </required_header>
  <id_info>
    <org_study_id>GZTO1201</org_study_id>
    <nct_id>NCT01578668</nct_id>
  </id_info>
  <brief_title>Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases</brief_title>
  <official_title>Phase 2 Study of Erlotinib Plus Pemetrexed/Cisplatin Treating Lung Adenocarcinoma With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether erlotinib plus pemetrexed, cisplatin are
      effective and safe in treating lung adenocarcinoma with brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-small lung cancer (NSCLC) is the leading cause of death in the world. Brain metastases
      are a frequent complication of NSCLC, especially in lung adenocarcinoma. 30-50% or more
      these patients will develop brain metastases at first time or during the treatment. Limited
      treatment options, whole brain radiotherapy (WBRT) combined with or without stereotactic
      radiosurgery (SRS) as the primary treatment approach, are available for brain metastases
      patients with poor survival. So the availability of effective therapies are therefore of
      great importance. Currently, two agents (erlotinib and pemetrexed) are reported more
      effective in lung adenocarcinoma patients with brain metastases. The heterogeneity of NSCLC
      tumors provides a strong rationale for using combination therapy with targeted agents that
      have different mechanisms of action, moreover different combination offering synergistic
      effects. So we investigate if erlotinib plus pemetrexed, cisplatin are effective and safe in
      treating lung adenocarcinoma with brain metastases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The objective response rate of brain metastases</measure>
    <time_frame>Patients will be followed for an expected average of 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The disease control response rate of disease</measure>
    <time_frame>Patients will be followed for an expected average of 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of patients</measure>
    <time_frame>2 years after first treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety</measure>
    <time_frame>2 years after first treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients</measure>
    <time_frame>3 years after the first treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Erlotinib, pemetrexed, cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 20th day before the next cycle, and until disease PD</description>
    <arm_group_label>Erlotinib, pemetrexed, cisplatin</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 8 cycles</description>
    <arm_group_label>Erlotinib, pemetrexed, cisplatin</arm_group_label>
    <other_name>ALIMTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin 20mg/m² iv on the 1st-3rd day of each cycle until PD or unacceptable toxicity or no more than 8 cycles</description>
    <arm_group_label>Erlotinib, pemetrexed, cisplatin</arm_group_label>
    <other_name>platinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>150 mg given orally (po), daily (QD), starting on the first day of the first cycle</description>
    <arm_group_label>erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological or cytological diagnosis of lung adenocarcinoma histology with brain
             metastases

          2. 18 years or older

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 3

          4. Appraisable intracranial disease, the presence of at least one lesion, and the sum of
             lesions which longest diameter &gt; 5 mm by brain MRI

          5. Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5^9/L, platelets 100 x
             10^9/L

          6. Total bilirubin 1.5 x upper limit of normal (ULN)

          7. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 x ULN in
             the absence of liver metastases, or &lt; 5 x ULN in case of liver metastases

          8. Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)

          9. If received brain radiotherapy, patients included at least 8 weeks after the end of
             radiotherapy.

        Exclusion Criteria:

          1. Mixed non-adenocarcinoma cell lung cancer histology

          2. Previous treatment with pemetrexed or tarceva

        4.Be allergic to pemetrexed or tarceva
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haihong Yang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first affiliated hospital of Guangzhou MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haihong Yang, Dr.</last_name>
    <phone>0862083062825</phone>
    <email>bjrf2009@yahoo.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first affiliated hospital of Guangzhou MC</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haihong Yang, Dr.</last_name>
      <phone>0862083062825</phone>
      <email>bjrf2009@yahoo.cn</email>
    </contact>
    <investigator>
      <last_name>Haihong Yang, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 6, 2013</lastchanged_date>
  <firstreceived_date>April 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Haihong Yang, MD, Pricipal investigator</investigator_full_name>
    <investigator_title>The first affiliated hospital of Guangzhou MC</investigator_title>
  </responsible_party>
  <keyword>lung adenocarcinoma</keyword>
  <keyword>brain metastases</keyword>
  <keyword>erlotinib</keyword>
  <keyword>pemetrexed</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
